Why Access Consortium Makes Sense For Industry And Regulators

The Access Consortium, established in 2007, serves as a model of regulatory convergence, providing a simplified pathway for both industry and regulators. Its members include Australia’s Therapeutic Goods Administration (TGA), Health Canada (HC), Singapore’s Health Sciences Authority (HSA), Swissmedic, and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). Access encourages collaboration to achieve a common objective: efficient evaluation and approval processes.

Through initiatives like work-sharing, Access minimizes redundancy and offers synchronized approval across participating nations, benefiting both industry and regulators. Additionally, recent engagements, such as joint pipeline meetings, demonstrate a commitment to promoting innovation and collaboration.

Learn more about how Access Consortium’s cooperation not only eases the burden for regulatory bodies, but also provides industry players with a more direct route to market, ultimately meeting the needs of patients worldwide.